Table 1 Clinical characteristics of TSHomas with concurrent thyroid cancer reported in literature and present cases
Reference | Age/Sex | Pituitary tumor | Thyroid cancer | Pre-op management | The order of surgeries | Radio-iodine ablation therapy Preparation (dose) | TSH level at the last follow up | Clinical outcome | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Size (cm) | Secreting hormone | Histologic type | Size (cm), multifocality | TNM stage | 1st surgery | 2nd surgery | Pituitary tumor | Thyroid cancer | |||||
Calle-Pascual [7] et al | 55/M | NR | TSH | FTC | 5.0 | NR | No | TT | TSA&TR | NR (35 mCi) | Undetectable on LT4 | Remission (1 year) | Remission (1 year) |
Gasparoni [19] et al | 37/F | 1.0 | TSH | PTC, | 2.0 | T2N0M0 | No | TT | No surgery for pituitary tumor | NR (150 mCi) | NR | Remission (NR) | NR |
Kishida [21] et al | 27/F | 1.0 | TSH | PTC | 3.0 | T2N1M0 | Octreotide | TSA&TR | Lobectomy | No | Normal range without LT4 | NR | Remission (9 months) |
Ohta [18] et al | 45/F | 1.5 | TSH | PTC | 2.0 | NR | Octreotide | TT | TR via right pterional approach | No | Normal range | Remission (4 months) | NR |
Gessl [20] et al | 22/F | 0.4 | TSH/PRL | FTC | 0.8 | T1N0M0 | No | TT | TSA&TR | NR (80 mCi) | 0.6 mU/L | Remission (NR) | NR |
Poggi [8] et al | 50/M | 0.3 | TSH | FTC | 1.7 | NR | No | TT | No surgery for pituitary tumor | No | 6.97 uIU/mL | NR | Remission (12 months) |
Nguyen [17] et al | 57/F | 2.6 | TSH/GH | PTC | 0.8, multifocal | NR | Octreotide | TT | No surgery for pituitary tumor | rhTSH (100 mCi) | 0.145 mIU/L | Remission (20 months) | Octreotide response |
Ünlütürk [23] et al | 38/F | 2.2 | TSH | PTC, Oncocytic variant | 4.0, multifocal | T3N1M0 | Octreotide | TT | TSA&TR - > gamma knife surgery | NR (150 mCi) | 3.4 ~ 3.7 mU/L | Stable residual tumor | Remission (84 months) |
27/F | 2.8 | TSH | PTC | 1.0, multifocal | T1N0M0 | Methimazole | TT | None | NR (150 mCi) | 4.7 mU/L | Residual tumor on lanreotide | Remission (6 months) | |
Perticone [14] et al | 47/M | 1.9 | TSH | FTC, Hürthle cell variant | 1.5 | T1bN0M0 | Lanreotide | TT | TSA&TR | rh TSH (106 mCi) | 0.1 mU/L | Remission (6 months) | Remission (1 year) |
46/M | 0.7 | TSH | PTC, Follicular variant | 1.2 | T1bN0M0 | Lanreotide | TSA&TR | TT | rh TSH (100 mCi) | 0.2 | Remission (5 years) | Remission (5 years) | |
42/M | 1.2 | TSH | PTC | NR, multifocal | T3bN1aM0 | No | TT | TSA&TR | NR (100 mCi) | < 0.1 and 0.3 | Remission (28 months) | Remission (28 months) | |
Present case | 59/M | 7.0 | TSH/GH | PTC | 0.5, multifocal | T1aN1aM0 | Octreotide | TT | TR via interhemispheric approach | Levothyroxine withdrawal (180 mCi) | 1.99 uIU/ml | Residual tumor on lanreotide | Remission (44 months) |